Amarin Corp Plc (AMRN)

[HDGabor]

Amarin Pharma Inc. et al v. West-Ward Pharmaceuticals Corp et al (2:16-cv-02525-MMD-NJK)

D- Please replace the sticky with this one. TIA, G

MOTION TO INTERVENE & MOTION TO VACATE JUDGMENT
UPDATE: SEE BELOW
- - - - - - - - - - -
401: INTERVENOR EPADI II’S MOTION TO INTERVENE PURSUANT TO FED. R. CIV. P. 24
401-1: INDEX OF EXHIBITS
401-2: Exhibit A: Email from Avi Silberberg, Esq. to Amarin’s CEO, John Thero, requesting that Amarin seek Rule 60 relief, dated November 9, 2020 (Sender and Reciept’s email addresses have been redacted)
401-3: Exhibit B: Yahoo Finance screenshot showing the collapse of Amarin’s stock price in the immediate aftermath of the Judgment, dated March 31, 2020
401-4: Exhibit C: True Excerpts from the Amicus Brief filed by the Aimed Alliance in support of Amarin’s Petition for Certiorari to the United States Supreme Court, dated March 4,2021
401-5: DECLARATION OF MICHAEL S. KASANOFF IN SUPPORT OF EPADI II’S MOTION TO INZERVENE PURSUANT TO FED. R. CIV. P. 24
401-6: CERTIFICATE OF SERVICE

405: INTERVENOR EPADI II’S MOTION TO VACATE JUDGMENT PURSUANT TO FED. R. CIV. P.
405-1: INDEX OF EXHIBITS
405-2: Exhibit A: Expert Report prepared by Dr. Gavin E. Jarvis, dated March 12, 2021
405-3: Exhibit B: Dr. Jarvis’s Curriculum Vitae
405-4: Exhibit C: Curfman, G., Bhatt, D.L. & Pencina, M., Federal Judge Invalidates Icosapent Ethyl Patents But Based on a Common Statistical Mistake, Nat. Biotehcnol 38, 939-941(2020)
405-5: Exhibit D: Abstract of the Paper supporting Curfman, G., Bhatt, D.L. & Pencina, M., Federal Judge Invalidates Icosapent Ethyl Patents But Based on a Common Statistical Mistake, Nat. Biotehcnol 38, 939-941(2020)
405-6: Exhibit E: Paper supporting Curfman, G., Bhatt, D.L. & Pencina, M., Federal Judge Invalidates Icosapent Ethyl Patents But Based on a Common Statistical Mistake, Nat. Biotehcnol 38, 939-941(2020)
405-7: Exhibit F: Kurabayashi et. al., Eicosapentaenoic acid effect on hyperlipedema in menopausal Japanese women. Obster Gynecol, 2000;96(4):521-8
405-8: DECLARATION OF MICHAEL S. KASANOFF IN SUPPORT OF EPADI II’S MOTION TO VACATE JUDGMENT PURSUANT TO FED. R. CIV. P. 24
405-9: CERTIFICATE OF SERVICE

407: VERIFIED PETITION FOR PERMISSION TO PRACTICE IN THIS CASE ONLY BY ATTORNEY NOT ADMITTED TO THE BAR OF THIS COURT AND DESIGNATION OF LOCAL COUNSEL

408: PLAINTIFFS’ RESPONSE TO MOTIONS OF PROPOSED INTERVENOR EPA DRUG INITIATIVE II (ECF NOS. 401 AND 405)

409: DEFENDANTS’ RESPONSE TO THE MOTION TO INTERVENE PURSUANT TO FED. R. CIV. P. 24 BY “EPADI II”

410: INTERVENOR EPADI II’S REPLY BRIEF
410-1: REPLY DECLARATION OF MICHAEL S KASANOFF
410-2: INDEX OF EXHIBITS
410-3: Exhibit A: Summary Exhibit showing the inconsistency between Dr. Heinecke’s deposition testimony and Kurabayashi Table 2.
4110-4: Exhibit B: Summary Exhibit entitled, “Dr. Heinecke Testimony: The Cropped Table 3 Kurabayashi Legend and Fatal Statistical Error.”
410-5: Exhibit C: Summary Exhibit entitled, “Cropped Table 3 Legend - Why It Matters.”
410-6: CERTIFICATE OF SERVICE
- - - - - - - - - - -
Best,
G